- On Thursday,
Pfizer asked the FDA to authorize its COVID-19 shot forkids ages 5 to 11. - That means kids could start getting vaccinated sometime around Halloween.
- The FDA could OK vaccines for kids ages 6 months to 5 years in November, Pfizer's timeline suggests.
Vaccines for kids have finally entered the home stretch.
Pfizer asked the Food and Drug Administration on Thursday to authorize a lower dose of its
The FDA could greenlight the shot for young kids sometime around Halloween, since the data take weeks to review.
Vaccines for even younger
Moderna data for kids 6 months and older would then be available in late 2021 or early 2022, the analysts said.
Vaccines can reduce severe disease among young kids
A recent study from the Centers for Disease Control and Prevention found that unvaccinated adults in the US were 11 times more likely to die and 10 times more likely to be hospitalized from COVID-19 than those who were fully vaccinated. In addition to offering kids protection, vaccinating them will probably make it harder for the virus to spread in the general population - particularly now that in-person school is in full swing.
"Our fundamental problem is we don't have enough adults immunized right now, and we don't have approval for the kids," Chris Beyrer, an epidemiologist at the Johns Hopkins Bloomberg School of Public Health, told Insider. "Until that changes, we're going to have ongoing transmission, unacceptably high rates."
Right now, 65% of all Americans are fully vaccinated. If all 48 million children under 12 got vaccinated in the US, that figure would rise to nearly 80%.
Young children may receive a lower dose
Since the FDA has fully approved Pfizer's vaccine for people 16 and older, pediatricians can legally prescribe the shot for "off-label" use in young kids. But health officials have said not to do so yet.
Children tend to develop more intense side effects after vaccines than adults, likely because their immune systems rev up quickly. So Pfizer and Moderna are each testing a lower dose of their vaccines among kids to avoid unnecessary
Pfizer's late-stage trial indicates that the lower dose - 10 micrograms, instead of the 30 given to adults - was safe among nearly 2,300 children ages 5 to 11. The trial also demonstrated that the vaccine produced a strong antibody response among younger kids. These results were comparable to the ones observed among people ages 16 to 25, who received the standard 30 micrograms, Pfizer said.
The trial is administering an even smaller dosage, 3 micrograms, to children ages 6 months to 5 years.
Moderna is similarly comparing its standard dose (100 micrograms) with lower doses for all age groups. Children ages 2 to 12 in the trial are receiving either 50 or 100 micrograms, and kids between 6 months and 2 years old are receiving 25, 50, or 100.
This story has been updated with new information. It was originally published September 15.